The MindMed study evaluates an investigational new drug formulation of lysergide D-tartrate (MM120) for adults with generalized anxiety disorder (GAD).

Currently in Phase 3, the study referred to as “Panorama” is a randomized, double-blind, placebo-controlled trial (Part A) with an open-label extension (Part B), evaluating the study drug against placebo in generalized anxiety disorder.

The study is designed to assess the efficacy and safety of this compound in patients diagnosed with GAD and to explore whether the investigational new drug MM120 offers a novel, effective therapeutic option for this challenging anxiety disorder.

Up to 375 participants aged 18 to 74 years diagnosed with GAD according to DSM-5 criteria and exhibiting clinically significant anxiety symptoms (HAM-A score ≥ 20) will be enrolled. Participants will be randomized to receive either MM120 at two different doses (50 µg or 100 µg) or matching placebo during the initial phase. Those who complete Part A may continue to Part B for longer-term treatment follow-up. Participants must meet diagnostic criteria for GAD.

This multicenter study will evaluate the efficacy and safety of this novel treatment approach over a 12-week double-blind phase with a single-dose administration, followed by a 40-week open-label extension phase.

Project Title: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder – Panorama
ClinicalTrials.gov ID: NCT06809595
Study Sponsor: Mind Medicine Inc.
Official Study Information: Clinicaltrials.gov, MindMed